 Anavex Life Sciences Corp NASDAQ: AVXL has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinsons Disease Dementia PDD study at the ADPD 2022 International Conference. MDS-UPDRS1 Total score improved significantly by -14.51 for. 